KAS
SABS icon

Kestra Advisory Services’s SAB Biotherapeutics SABS Stock Holding History

Kestra Advisory Services’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$194K Sell
49,811
-11,930
-19% -$44.4K ﹤0.01% 3110
2026
Q1 		$236K Buy
61,741
+50,191
+435% +$200K ﹤0.01% 2828
2025
Q4 		$43.2K Sell
11,550
-380
-3% -$1.25K ﹤0.01% 4032
2025
Q3 		$24K Hold
11,930
– – ﹤0.01% 2879
2025
Q2 		$20.9K Hold
11,930
– – ﹤0.01% 2798
2025
Q1 		$16.2K Hold
11,930
– – ﹤0.01% 2696
2024
Q4 		$45.3K Hold
11,930
– – ﹤0.01% 2614
2024
Q3 		$32.2K Buy
+11,930
New +$33K ﹤0.01% 2518
2024
Q1 		– Sell
-8,800
Closed -$60.5K – 2520
2023
Q4 		$60.5K Buy
8,800
+6,700
+319% +$56.2K ﹤0.01% 2210
2023
Q3 		$13.2K Hold
2,100
– – ﹤0.01% 2092
2023
Q2 		$17.4K Buy
2,100
+1,000
+91% +$8.19K ﹤0.01% 2082
2023
Q1 		$4.84K Hold
1,100
– – ﹤0.01% 2041
2022
Q4 		$6.49K Hold
1,100
– – ﹤0.01% 2240
2022
Q3 		$8K Hold
1,100
– – ﹤0.01% 2085
2022
Q2 		$16K Buy
+1,100
New +$23.1K ﹤0.01% 2097

Other funds holding SABS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Kestra Advisory Services's SABS Position: Q2 2026 in Review

Kestra Advisory Services reduced its SAB Biotherapeutics (SABS) stake by 19% in Q2 2026, selling an estimated $44.4K and leaving 49,811 shares worth $194K. The position accounts for ﹤0.01% of the portfolio, ranked #3110.

Kestra Advisory Services first reported a position in SABS in Q2 2022 and has held it in 15 quarters since. The position peaked at $236K in Q1 2026. 49 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

  • Kestra Advisory Services held 49,811 shares of SAB Biotherapeutics worth $194K as of Q2 2026.
  • Kestra Advisory Services sold 11,930 SAB Biotherapeutics shares in Q2 2026, an estimated $44.4K.
  • SAB Biotherapeutics made up ﹤0.01% of Kestra Advisory Services's portfolio in Q2 2026, its #3110 holding.
  • Kestra Advisory Services first reported a position in SAB Biotherapeutics in Q2 2022 and has held it in 15 quarters since.
  • Kestra Advisory Services's SAB Biotherapeutics position peaked at $236K in Q1 2026.
  • 49 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on Kestra Advisory Services's 13F filing for Q2 2026, filed 28 Jul 2026.